

attendance, and registrations will be accepted on a first-come, first-served basis. To register for the meeting, please visit <http://peerreview.versar.com/epa/pfoa/registration.html>, complete the online registration form, and submit the required information. You can also register through U.S. Postal Service or overnight/priority mail by sending the necessary registration information (see Registration Information) to the Versar Meeting Coordinator, Ms. Betzy Colon, Versar, Inc., 6850 Versar Center, Springfield, VA 22151; telephone: (703) 642-6727. Registrations sent via U.S. Postal Service or overnight/priority mail must be received by August 18, 2014.

**Registration Information:** To register for the meeting online or via mail, please provide your full name, title, organization or affiliation, and contact information. You must also indicate which day(s) you plan to attend the meeting.

**FOR FURTHER INFORMATION CONTACT:**

Questions regarding logistics or registration for the external peer review meeting should be directed to Ms. Betzy Colon, Versar, Inc., 6850 Versar Center, Springfield, VA, 22151; telephone: (703) 642-6727; or via email at [bcolon@versar.com](mailto:bcolon@versar.com). For additional information concerning EPA's draft health effects documents, please contact Joyce Donohue at U.S. EPA, Office of Water, Health and Ecological Criteria Division (Mail Code 4304T), 1200 Pennsylvania Avenue NW., Washington, DC 20460; telephone: (202) 566-1098; or email: [donohue.joyce@epa.gov](mailto:donohue.joyce@epa.gov).

**SUPPLEMENTARY INFORMATION:**

**I. Information on the Draft Health Effects Documents**

EPA released the draft health effects documents for Perfluorooctanoic Acid (PFOA) and Perfluorooctane Sulfonate (PFOS) for purposes of public comment (scientific views) and peer review on February 28, 2014 (<http://www.gpo.gov/fdsys/pkg/FR-2014-02-28/pdf/2014-04455.pdf>), 79 FR 11429. The 60-day public comment period ended on April 29, 2014. EPA will consider peer reviewer and public comments when finalizing the documents. Once the health effects documents are finalized, they will be utilized to develop lifetime health advisory values for each chemical. The draft documents, draft charge questions, and public comments submitted during the public comment period may be viewed at <http://www.regulations.gov> (Docket ID No. EPA-HQ-OW-2014-0138). The draft documents and charge questions may also be viewed at <http://peerreview.versar.com/epa/pfoa>.

**II. Information About the Peer Reviewers**

Consistent with guidelines for the peer review of highly influential scientific assessments, EPA tasked a contractor (Versar, Inc.) to assemble six to seven experts to evaluate the draft documents. Versar, Inc. evaluated 29 candidates who were either nominated during a previous public comment period (February 28, 2014 to March 21, 2014) or were identified by Versar to augment the list of publically-nominated candidates. Versar narrowed the list of potential reviewers to 15 candidates and solicited public comments on the interim list on April 30, 2014 (<http://www.gpo.gov/fdsys/pkg/FR-2014-04-30/pdf/2014-09888.pdf>), 79 FR 24419. Using the selection criteria described in the **Federal Register** dated February 28, 2014 (<http://www.gpo.gov/fdsys/pkg/FR-2014-02-28/pdf/2014-04455.pdf>), 79 FR 11429, Versar selected the final seven peer reviewers who, collectively, best provide expertise spanning the multiple subject matter areas covered by the draft documents and, to the extent feasible, best provide a balance of perspectives. Additional information on the scientific peer reviewer selection process can be found at: <http://peerreview.versar.com/epa/pfoa>.

The final list of seven selected peer reviewers is provided below.

1. Dr. James Bruckner—University of Georgia
2. Dr. Deborah Cory-Slechta—University of Rochester School of Medicine and Dentistry
3. Dr. Jamie DeWitt—East Carolina University
4. Dr. Jeffrey Fisher—U.S. Food & Drug Administration
5. Dr. William Hayton—The Ohio State University (Emeritus)
6. Dr. Matthew Longnecker—National Institute of Environmental Health Sciences
7. Dr. Angela Slitt—University of Rhode Island

EPA requests that no individual or organization contact in any way the contractor (Versar, Inc.) or the peer reviewers regarding the subject of the peer review meeting, send them written materials regarding the subject of the meeting, or make any offers or requests to any of them that appear to be linked to their participation in the peer review. The Contractor (Versar, Inc.) will direct the reviewers to report any such contacts to the Contractor (Versar, Inc), who will take appropriate action in consultation with EPA to ensure the independence and impartiality of the peer review.

**III. Information About the Peer Review Meeting**

The peer reviewers have been charged with evaluating and preparing written comments on the draft PFOA and PFOS health effects documents. Specifically, reviewers will provide general comments, their overall impressions of the documents, and responses to 12 charge questions. Reviewers will also consider the appropriateness of the quality, accuracy, and relevance of the data in the documents. Comments submitted to EPA's public docket (Docket ID number EPA-HQ-OW-2014-0138) during each document's 60-day public comment period will also be provided to the peer reviewers ahead of the meeting for their consideration.

Peer reviewers will participate in the two-day peer review meeting to discuss the scientific basis supporting EPA's draft health effects documents. Following the peer review meeting, Versar will provide a peer review summary report to EPA containing the comments and recommendations from the peer reviewers. The final peer review report will also be made available to the public. In preparing the final health effects documents, EPA will consider Versar's report of the comments and recommendations from the external peer review meeting, as well as written public comments received through the official public docket.

Dated: July 2, 2014.

**Nancy K. Stoner,**

*Acting Assistant Administrator, Office of Water.*

[FR Doc. 2014-16176 Filed 7-9-14; 8:45 am]

**BILLING CODE 6560-50-P**

**FEDERAL RESERVE SYSTEM**

**Formations of, Acquisitions by, and Mergers of Bank Holding Companies**

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 *et seq.*) (BHC Act), Regulation Y (12 CFR part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank

indicated. The applications will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than August 4, 2014.

A. Federal Reserve Bank of Kansas City (Dennis Denney, Assistant Vice President) 1 Memorial Drive, Kansas City, Missouri 64198-0001:

1. *Exchange Company*, Kearney, Nebraska; to acquire 100 percent of the voting shares of JCK, Inc., parent of The First National Bank and Trust Company of Junction City, both in Junction City, Kansas.

Board of Governors of the Federal Reserve System, July 7, 2014.

**Michael J. Lewandowski,**

*Assistant Secretary of the Board.*

[FR Doc. 2014-16140 Filed 7-9-14; 8:45 am]

**BILLING CODE 6210-01-P**

---

## FEDERAL TRADE COMMISSION

[File No. 141 0098]

### Actavis plc and Forest Laboratories; Analysis of Proposed Consent Order to Aid Public Comment

**AGENCY:** Federal Trade Commission.

**ACTION:** Proposed Consent Agreement.

**SUMMARY:** The consent agreement in this matter settles alleged violations of federal law prohibiting unfair methods of competition. The attached Analysis of Agreement Containing Consent Order to Aid Public Comment describes both the allegations in the draft complaint and the terms of the consent order—embodied in the consent agreement—that would settle these allegations.

**DATES:** Comments must be received on or before July 30, 2014.

**ADDRESSES:** Interested parties may file a comment at <https://ftcpublic.commentworks.com/ftc/actavisdivestapp> online or on paper, by following the instructions in the Request for Comment part of the **SUPPLEMENTARY INFORMATION** section below. Write “Actavis plc and Forest Laboratories—Consent Agreement; File

No. 141 0098” on your comment and file your comment online at <https://ftcpublic.commentworks.com/ftc/actavisdivestapp> by following the instructions on the web-based form. If you prefer to file your comment on paper, mail your comment to the following address: Federal Trade Commission, Office of the Secretary, 600 Pennsylvania Avenue NW., Suite CC-5610 (Annex D), Washington, DC 20580, or deliver your comment to the following address: Federal Trade Commission, Office of the Secretary, Constitution Center, 400 7th Street SW., 5th Floor, Suite 5610 (Annex D), Washington, DC 20024.

**FOR FURTHER INFORMATION CONTACT:**

Christine Tasso, Bureau of Competition, (202-326-2232), 600 Pennsylvania Avenue NW., Washington, DC 20580.

**SUPPLEMENTARY INFORMATION:** Pursuant to Section 6(f) of the Federal Trade Commission Act, 15 U.S.C. 46(f), and FTC Rule 2.34, 16 CFR 2.34, notice is hereby given that the above-captioned consent agreement containing consent order to cease and desist, having been filed with and accepted, subject to final approval, by the Commission, has been placed on the public record for a period of thirty (30) days. The following Analysis to Aid Public Comment describes the terms of the consent agreement, and the allegations in the complaint. An electronic copy of the full text of the consent agreement package can be obtained from the FTC Home Page (for June 30, 2014), on the World Wide Web, at <http://www.ftc.gov/os/actions.shtm>.

You can file a comment online or on paper. For the Commission to consider your comment, we must receive it on or before July 30, 2014. Write “Actavis plc and Forest Laboratories—Consent Agreement; File No. 141 0098” on your comment. Your comment—including your name and your state—will be placed on the public record of this proceeding, including, to the extent practicable, on the public Commission Web site, at <http://www.ftc.gov/os/publiccomments.shtm>. As a matter of discretion, the Commission tries to remove individuals’ home contact information from comments before placing them on the Commission Web site.

Because your comment will be made public, you are solely responsible for making sure that your comment does not include any sensitive personal information, like anyone’s Social Security number, date of birth, driver’s license number or other state identification number or foreign country equivalent, passport number, financial

account number, or credit or debit card number. You are also solely responsible for making sure that your comment does not include any sensitive health information, like medical records or other individually identifiable health information. In addition, do not include any “[t]rade secret or any commercial or financial information which . . . is privileged or confidential,” as discussed in Section 6(f) of the FTC Act, 15 U.S.C. 46(f), and FTC Rule 4.10(a)(2), 16 CFR 4.10(a)(2). In particular, do not include competitively sensitive information such as costs, sales statistics, inventories, formulas, patterns, devices, manufacturing processes, or customer names.

If you want the Commission to give your comment confidential treatment, you must file it in paper form, with a request for confidential treatment, and you have to follow the procedure explained in FTC Rule 4.9(c), 16 CFR 4.9(c).<sup>1</sup> Your comment will be kept confidential only if the FTC General Counsel, in his or her sole discretion, grants your request in accordance with the law and the public interest.

Postal mail addressed to the Commission is subject to delay due to heightened security screening. As a result, we encourage you to submit your comments online. To make sure that the Commission considers your online comment, you must file it at <https://ftcpublic.commentworks.com/ftc/actavisdivestapp> by following the instructions on the web-based form. If this Notice appears at <http://www.regulations.gov/#!home>, you also may file a comment through that Web site.

If you file your comment on paper, write “Actavis plc and Forest Laboratories—Consent Agreement; File No. 141 0098” on your comment and on the envelope, and mail your comment to the following address: Federal Trade Commission, Office of the Secretary, 600 Pennsylvania Avenue NW., Suite CC-5610 (Annex D), Washington, DC 20580, or deliver your comment to the following address: Federal Trade Commission, Office of the Secretary, Constitution Center, 400 7th Street SW., 5th Floor, Suite 5610 (Annex D), Washington, DC 20024. If possible, submit your paper comment to the Commission by courier or overnight service.

Visit the Commission Web site at <http://www.ftc.gov> to read this Notice

<sup>1</sup>In particular, the written request for confidential treatment that accompanies the comment must include the factual and legal basis for the request, and must identify the specific portions of the comment to be withheld from the public record. See FTC Rule 4.9(c), 16 CFR 4.9(c).